FOI 9464

1. I would be grateful if you could send the most recent planning document(s) for the diagnosis and treatment of **Alzheimer's Disease,** whether these are from the Trust, Integrated Care Board (ICB), or the region. I am particularly interested in planning documents that cover lumbar punctures (CSF) and Blood Biomarker testing. –

   Not aware of any planning documents, but cannot comment regarding ICB or region

2. To what extent are there plans for service improvement of diagnosing **Alzheimer's Disease**?

	Yes / No
Implementation of plans has started	
A plan exists and implementation has not started	
A plan is being developed	
There is no plan	
Other – please state	Not aware of any planning documents, but can not comment regarding ICB or region

3. Are the plans for service improvement of diagnosing **Alzheimer's Disease** related to:

	Yes / No
Cognitive assessment services	n/a (see above)
Biomarker services	
None / neither	

4. Which of the following services does the Trust have in place in preparation for increased service delivery for **Alzheimer's Disease**?

	Related to administration of **lumbar punctures** Yes / No	Related to **Blood Biomarker testing** Yes / No
Budget	No	No

People	No	No
Training	No	No
Clinic space / capacity	No	No
Governance arrangements	No	No

5. How many lumbar puncture procedures to test for **Alzheimer's Disease** were performed in the last three-month period for which data are available?

	Number of procedures
Number of lumbar punctures	0

6. Please provide the number of BBM tests for **Alzheimer's Disease** conducted over the last three-months, regardless of whether they were carried out within your organisation or sent to an external pathology laboratory.

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of Blood Biomarker tests	0	0	0

7. Which of the following biomarker tests were used to detect **Alzheimer's Disease**?

	Yes / No
pTau181 immunoassay tests	No
pTau217 immunoassay tests	No

8. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers samples for **pTau181** and **pTau217** immunoassay testing for **Alzheimer's Disease**?

Full name of Trust or organisation(s)

None

9. How many **pTau181** immunoassay tests were conducted to test for **Alzheimer's Disease** in the last three-months?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau181 tests	0	0	0

10. Is **pTau181** testing for Alzheimer's Disease linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau181 Testing associated with clinical trial activity	No

11. How many **pTau181** immunoassay tests were conducted for **Alzheimer's Disease** as part of a clinical trial?

Number of pTau181 tests	0

12. How many **pTau217** immunoassay tests were conducted to test for **Alzheimer's Disease** in the last three-months?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau217 tests	0	0	0

13. Is **pTau217** testing for **Alzheimer's Disease** linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau217 Testing associated with clinical trial activity	No

14. How many **pTau217** immunoassay tests were conducted for **Alzheimer's Disease** as part of a clinical trial?

Number of pTau217 tests	0